Purpose: We aimed to investigate the associations between polymorphisms of interleukin-1A (IL-1A), IL-1B,and IL-1 receptor antagonist (IL-1RN) and prostate cancer (PCa) risk. Materials and
Methods: A comprehensivesearch for articles of MEDLINE and EMBASE databases and bibliographies of retrieved articles publishedup to August 3, 2014 was performed. Methodological quality assessment of the trials was based on a standardquality scoring system. The meta-analysis was performed using STATA 12.0.
Results: We included 9 studies (1study for IL-1A, 5 studies for IL-1B, and 3 studies for IL-1RN), and significant association was found betweenpolymorphisms of IL-1B-511 (rs16944) as well as IL-1B-31 (rs1143627) and PCa risk. IL-1B-511 (rs16944)polymorphism was significantly associated with PCa risk in homozygote and recessive models, as well as allelecontrast (TT vs CC: OR, 0.74; 95%CI, 0.58-0.94; P=0.012; TT vs TC+CC; OR, 0.79; 95%CI, 0.63-0.98; P=0.033;T vs C: OR, 0.86; 95%CI, 0.77-0.96; P=0.008). The association between IL-1B-31 (rs1143627) polymorphism andPCa risk was weakly significant under a heterozygote model (OR, 1.35; 95%CI, 1.00-1.80; P=0.047).
Conclusions:Sequence variants in IL-1B-511 (rs16944) and IL-1B-31 (rs1143627) are significantly associated with PCa risk,which provides additional novel evidence that proinflammatory cytokines and inflammation play an importantrole in the etiology of PCa.